Bowen provides discovery research and discovery services of recombinant proteins and antibodies. Bowen Antibody Discovery Platform (BoAb) includes the following features:
- Advanced Immunization methods: Near Lymph nodes immunization.
- Antigens selection: Proteins, peptides, DNA, mRNA, and cells.
- High efficiency adjuvant: Water-soluble high-efficiency adjuvant for enhanced immune responses with fewer side effects.
- Sequence Identification: Target cell FACS selection/sequencing or phage display panning selection.
- Sequence Validation: Binding and affinity screening for optimal sequences.
- Developability Assessments: Expression, specificity, solubility, and stability assessments.
Bowen also offers Beacon® Platform services in association with Collaborator
- Fast turnaround: Precise single cell selection and sequencing
- Multiple species: mouse, rabbit, rat, alpaca, human
- Multiplex assays: Multiple parameters selections
- High throughput: Parallel interrogation of thousand individual cell or targets
Bowen provides variety of analytical assays in protein and antibody drug developability assessment with Collaborator:
- Engineering: design, engineer, optimization, humanization, testing
- Expression: bacterial and mammalian hosts, Transient and stable expression
- Purification: affinity (nickel, protein A, anti-Flag, streptavidin), size exclusive, ion exchange
- Assessment: affinity, specificity, solubility, stability, internalization, cytotoxicity (killing assay), T cell activation, ADCC, cytokine release
Bowen provides small animal assays at AAALAL accredited animal facility at UMASS Chan.
Bowen has accessibility of full-scale preclinical drug evaluation program through AAALAC-accredited facilities in China.
Bowen offers regulatory services in collaboration with experts in regulatory affairs of FDA and CFDA for biopharmaceutical, nutraceutical, cosmetics and diagnostics industries.